

1 Rachel Krevans (SBN 116421)  
MORRISON & FOERSTER LLP  
425 Market Street  
2 San Francisco, California 94105-2482  
Telephone: 415.268.7000  
3 Facsimile: 415.268.7522  
rkrevans@mofo.com

4 Grant J. Esposito (*pro hac vice*)  
MORRISON & FOERSTER LLP  
250 West 55th Street  
5 New York, NY 10019-9601  
Telephone: 212.468.8000  
6 Facsimile: 212.468.7900  
gesposito@mofo.com

7 Erik J. Olson (SBN 175815)  
MORRISON & FOERSTER LLP  
755 Page Mill Road  
8 Palo Alto, California 94304  
Telephone: 650.813.5600  
9 Facsimile: 650.494.0792  
ejolson@mofo.com

10 *Attorneys for Defendant Sandoz Inc.*

Vernon M. Winters (SBN 130128)  
Alexander D. Baxter (SBN 281569)  
SIDLEY AUSTIN LLP  
555 California Street, Suite 2000  
San Francisco, CA 94104-1503  
Telephone: 415.722.1200  
Facsimile: 415.772.7400  
vwinters@sidley.com

Nicholas Groombridge (*pro hac vice*)  
Eric Alan Stone (*pro hac vice*)  
Jennifer H. Wu (*pro hac vice*)  
Jennifer Gordon  
Peter Sandel (*pro hac vice*)  
Michael T. Wu (*pro hac vice*)  
1285 Avenue of the Americas  
New York, NY 10019-6064  
Telephone: 212.373.3000  
Facsimile: 212.757.3990  
ngroombridge@paulweiss.com

13 Wendy A. Whiteford (SBN 150283)  
Lois M. Kwasigroch (SBN 130159)  
One Amgen Center Drive  
14 Thousand Oaks, CA 91320-1789  
Telephone: 805.447.1000  
15 Facsimile: 805.447.1010  
wendy@amgen.com

16 *Attorneys for Plaintiffs Amgen Inc. and  
17 Amgen Manufacturing, Limited*

18  
19 **UNITED STATES DISTRICT COURT**  
20 **NORTHERN DISTRICT OF CALIFORNIA**

21 AMGEN INC. and  
22 AMGEN MANUFACTURING, LIMITED,

23 Plaintiffs,

24 vs.

25 SANDOZ INC., SANDOZ  
INTERNATIONAL GMBH, and  
26 SANDOZ GMBH,

27 Defendants.

Case No. 3:14-cv-04741-RS

**NOTICE OF MOTION AND  
JOINT MOTION TO LIFT STAY  
OF PATENT PROCEEDINGS**

1 **NOTICE OF MOTION**

2 PLEASE TAKE NOTICE that Plaintiffs Amgen Inc. and Amgen Manufacturing,  
3 Limited (together, “Amgen”) and Defendant Sandoz Inc. (“Sandoz”) hereby jointly move for an  
4 order from the Court lifting the current stay in the case as to Amgen’s claims of patent  
5 infringement and Sandoz’s related counterclaims. This Motion is based on this Notice of  
6 Motion, the accompanying Memorandum of Points and Authorities, and the proposed order  
7 submitted herewith, all papers and pleadings on file in this action, and all matters of which the  
8 Court may take judicial notice. Pursuant to Civil Local Rule 7-1(b), the parties request that this  
9 Motion be determined without oral argument.

10 **STATEMENT OF REQUESTED RELIEF**

11 The parties move the Court for an order lifting the current stay of Amgen’s patent  
12 infringement claims and Sandoz’s related counterclaims, and scheduling a case management  
13 conference on October 1, 2015.

14 **MEMORANDUM OF POINTS AND AUTHORITIES**

15 The parties seek to lift the current stay of these proceedings so that they can reach an  
16 adjudicated resolution of Amgen’s patent infringement claims and Sandoz’s related  
17 counterclaims.

18 On March 19, 2015, the Court issued its order on the parties’ cross-motions for  
19 judgment on the pleadings and Amgen’s motion for a preliminary injunction, dismissing  
20 Amgen’s claims under the California unfair competition laws and for conversion. Dkt. No. 105.  
21 On March 25, at the parties’ request, the Court stayed all proceedings not addressed by the  
22 Court’s March 19 Order, pending the Federal Circuit’s opinion on appeal. The circuit issued a  
23 panel opinion on July 21, 2015, finding that Sandoz did not violate the Biologics Price  
24 Competition and Innovation Act of 2009 (“BPCIA”) by failing to disclose its aBLA by the  
25 statutory deadline, and that Sandoz’s pre-approval notice of commercial marketing was  
26 ineffective. *Amgen Inc. v. Sandoz Inc.*, No. 2015-1499, 2015 WL 4430108 (Fed. Cir. Jul. 21,  
27 2015). The parties are each currently seeking *en banc* review of aspects of that opinion.  
28

1 The Federal Circuit has now ruled on the BPCIA issues and state law claims raised in  
2 Amgen's appeal. Accordingly, the parties respectfully request the Court lift the stay on the  
3 proceedings in this case so that the parties may resolve Amgen's patent infringement claims and  
4 Sandoz's related counterclaims.

5 The district court has discretion to lift a stay of litigation. *Ho Keung Tse v. Apple, Inc.*,  
6 No. C 06-06573 SBA, 2013 WL 5302587, at \*2 (N.D. Cal. 2013). If the circumstances  
7 originally supporting a stay have changed, a stay is appropriately lifted. *Id.* That is the case here.  
8 The parties sought a stay of the patent infringement claims in this case to allow the Federal  
9 Circuit to review the parties' claims and counterclaims relating to the interpretation of the  
10 BPCIA, which are separable from and not intertwined with the patent infringement and validity  
11 claims and counterclaims. The Federal Circuit previously issued an injunction pending appeal  
12 preventing Sandoz from launching its product, and the panel opinion extended that injunction  
13 through September 2, 2015. *Amgen v. Sandoz*, 2015 WL 4430108, at \*13. The parties agree  
14 that, in light of the Federal Circuit's resolution of the appeal, the stay may be lifted and  
15 Amgen's patent infringement claims should proceed.

16 The parties request the Court lift the stay and schedule a case management conference  
17 on October 1, 2015, when the Court has indicated it is available. The parties also propose that  
18 they submit a case management statement with a proposed case schedule ten days prior to the  
19 case management conference. Except for the date for Sandoz International GmbH and Sandoz  
20 GmbH to move, answer, or otherwise respond to the complaint for either entity, the parties  
21 propose that all pending or previously-set deadlines in this matter, including but not limited to  
22 the date for the Invalidity Contentions and accompanying document production under Patent  
23 L.R. 3-3 and 3-4, be tolled until new dates to be set by the Court in a further scheduling order.  
24 The parties further agree and propose that, to ensure an orderly start to the case and to enable  
25 the Court to discuss all procedural matters with the parties, no discovery will be served and no  
26 motions will be filed (except for any motion on behalf of Sandoz International GmbH or  
27 Sandoz GmbH in response to the complaint) until after the case management conference, and  
28

1 each party will describe in the case management statement its plans for discovery and any  
2 motions it intends to bring at the initial stages of the case.

3 A proposed order accompanies this motion.  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

1 Date: September 4, 2015

2  
3 /s/ Rachel Krevans

4 Rachel Krevans (SBN 116421)  
5 MORRISON & FOERSTER LLP  
6 425 Market Street  
7 San Francisco, California 94105-2482  
8 Telephone: 415.268.7000  
9 Facsimile: 415.268.7522  
10 rkrevans@mofo.com

11 *Attorneys for Defendant Sandoz Inc.*

12 OF COUNSEL:

13 Grant J. Esposito (*pro hac vice*)  
14 MORRISON & FOERSTER LLP  
15 250 West 55th Street  
16 New York, NY 10019-9601  
17 Telephone: 212.468.8000  
18 Facsimile: 212.468.7900  
19 gesposito@mofo.com

20 Erik J. Olson (SBN 175815)  
21 MORRISON & FOERSTER LLP  
22 755 Page Mill Road  
23 Palo Alto, California 94304  
24 Telephone: 650.813.5600  
25 Facsimile: 650.494.0792  
26 ejolson@mofo.com

3 /s/ Vernon M. Winters

4 Vernon M. Winters (SBN 130128)  
5 Alexander D. Baxter (SBN 281569)  
6 SIDLEY AUSTIN LLP  
7 555 California Street, Suite 2000  
8 San Francisco, CA 94104  
9 Telephone: (415) 772-1200  
10 Facsimile: (415) 772-7400  
11 vwinters@sidley.com

12 *Attorneys for Plaintiffs Amgen Inc. and  
13 Amgen Manufacturing, Limited*

14 OF COUNSEL:

15 Nicholas Groombridge (*pro hac vice*)  
16 Eric Alan Stone (*pro hac vice*)  
17 Jennifer H. Wu (*pro hac vice*)  
18 Jennifer Gordon  
19 Peter Sandel (*pro hac vice*)  
20 Michael T. Wu (*pro hac vice*)  
21 PAUL, WEISS, RIFKIND, WHARTON  
22 & GARRISON LLP  
23 1285 Avenue of the Americas  
24 New York, NY 10019  
25 Telephone: (212) 373-3000  
26 Facsimile: (212) 757-3990  
27 ngroombridge@paulweiss.com

28 Wendy A. Whiteford (SBN 150283)  
Lois M. Kwasigroch (SBN 130159)  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, CA 91320-1789  
Telephone: (805) 447-1000  
Facsimile: (805) 447-1010  
wendy@amgen.com

**ATTESTATION**

I, Vernon M. Winters, am the ECF user whose user ID and password are being used to file the foregoing document. Pursuant to Civil Local Rule 5-1(i)(3), I hereby attest that concurrence in the filing of this document has been obtained from Rachel Krevans.

Dated: September 4, 2015

/s/ Vernon M. Winters

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28



1 Amgen brought this action, asserting claims of unfair competition and conversion under  
2 California state law and patent infringement; Sandoz counterclaimed. The Court dismissed  
3 Amgen's claims under California state law. Dkt. No. 105. The Court then granted Rule 54(b)  
4 judgment on the dismissed claims and stayed all remaining claims in this action, pending the  
5 Federal Circuit's resolution of Amgen's appeal. Dkt. No. 111. The circuit issued a panel  
6 opinion on July 21, 2015. *Amgen Inc. v. Sandoz Inc.*, No. 2015-1499, 2015 WL 4430108 (Fed.  
7 Cir. Jul. 21, 2015). The parties are each currently seeking *en banc* review of aspects of that  
8 opinion. The parties now jointly request that the Court lift the stay on the remaining claims.

9 Having considered the parties' joint motion to lift the stay of patent proceedings in this  
10 case, and good cause appearing therefore, the Court GRANTS the motion and ORDERS as  
11 follows:

- 12 • The stay on all remaining proceedings in this case (*see* Dkt. No. 111) is lifted.
- 13 • A case management conference is scheduled for October 1, 2015, at 10:00 AM.
- 14 • The deadline for Sandoz International GmbH and Sandoz GmbH to move,  
15 answer, or otherwise respond to the complaint for either entity remains tolled  
16 until twenty days after the entry of this Order. *See* Dkt. No. 111, at 3.
- 17 • The parties shall submit a case management statement by September 21, 2015,  
18 proposing a new schedule for this case, including new dates for the Invalidity  
19 Contentions and accompanying document production under Patent L.R. 3-3 and  
20 3-4. These deadlines and any other pending or previously-set deadlines under  
21 the Federal Rules of Civil Procedure, Civil Local Rules, Patent Local Rules, or  
22 any order of this Court, except for the deadline for Sandoz International GmbH  
23 and Sandoz GmbH to move, answer, or otherwise respond to the complaint, shall  
24 be tolled until new dates to be set by the Court in a further scheduling order.
- 25 • No discovery shall be served and no motions shall be filed (except for any  
26 motion on behalf of Sandoz International GmbH or Sandoz GmbH in response to  
27 the complaint) until after the case management conference. Each party shall



1 describe in the case management statement its plans for discovery and any  
2 motions it intends to bring at the initial stages of the case.

3  
4 **IT IS SO ORDERED.**

5 Date: September \_\_, 2015

6  
7 \_\_\_\_\_  
8 HONORABLE RICHARD SEEBORG  
9 UNITED STATES DISTRICT JUDGE  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26